Sofosbuvir

Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

Retrieved on: 
Monday, November 13, 2023
SOF, Viral, Food, Plasma, AASLD, Risk, NS5A, Patient, Sofosbuvir, Atea, Pharmacokinetics, Liver, NS5B, Hepatitis C virus, HCV, Doctor of Philosophy, Bemnifosbuvir, Pharmaceutical industry, Boston

BOSTON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the presentation of two posters supporting the combination of bemnifosbuvir, an oral nucleotide polymerase inhibitor, and ruzasvir, an oral NS5A inhibitor, as a potential treatment for Hepatitis C Virus (HCV) at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting 2023, being held from November 10-14, 2023 in Boston, MA.

Key Points: 
  • “Results from these two presented studies further support the potential use of these two drug candidates in combination as a novel treatment for HCV.
  • Phase 1 data demonstrate that coadministration of bemnifosbuvir and ruzasvir was well tolerated and not affected by food or concomitant dosing, indicating a low risk of drug-drug interactions,” said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals.
  • These Phase 1 data support the continued clinical evaluation of these two potent drug candidates in combination for the treatment of HCV.
  • Results from an in vitro study demonstrate that the combination of bemnifosbuvir and ruzasvir has potent pan-genotypic antiviral activity against major HCV NS5A and NS5B RAVs and hard-to-treat sub-genotypes.

Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

Retrieved on: 
Wednesday, November 8, 2023
University of Washington Department of Global Health, Stanford University, Bio, Infection, Therapy, Viral, Biotechnology, Herpes simplex virus, BS, MD, Publication, Doctor of Philosophy, Gilead Sciences, Sofosbuvir, University, Assembly, HCV, Virology, Chemistry, Patient, HDV, HBV, SAN, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar is an infectious disease specialist and seasoned executive whose experience has focused on the development of new therapies in viral diseases including chronic hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis D virus (HDV) infections.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer.
  • “We are excited to have Dr. Gaggar join Assembly Bio’s leadership team at an incredibly important time for the organization,” said Jason Okazaki, chief executive officer and president.
  • Dr. Gaggar was a clinical fellow in infectious diseases at the University of California, San Francisco, where he also served as chief resident.
  • He received his MD and PhD from the University of Washington and his BS in chemistry from Stanford University.

Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model

Retrieved on: 
Wednesday, October 25, 2023
Liver, Neoplasm, HCC, Mouse, Health, Conditional sentence, Virus, Sofosbuvir, Artificial intelligence, Scripps Research, Growth, Liver cancer, HCV, Fatty liver disease, DRS, Velpatasvir, HEPA, Cancer, Pharmaceutical industry, Medical imaging, Dietary supplement

The study was published in the peer-reviewed, open access scientific journal, Viruses, and was conducted by Drs.

Key Points: 
  • The study was published in the peer-reviewed, open access scientific journal, Viruses, and was conducted by Drs.
  • Winston Stauffer, Philippe Gallay, and colleagues at The Scripps Research Institute (La Jolla, California).
  • Sofosbuvir, velpatasvir and rencofilstat treatments initiated at week 16 all eliminated HCV infection.
  • Not only could rencofilstat have an enormous impact on human health, but the investment growth opportunities associated with treating these high-need, global-scale diseases are equally large.”
    Hepion recently announced a new mechanism by which rencofilstat exerts anti-cancer activity in liver cancer and the drug’s anti-cancer activity in numerous cell lines representing 86% of cancer types.

Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries

Retrieved on: 
Thursday, July 13, 2023
Biotechnology, AIDS, Hospitals, Health, Pharmaceutical, Penta, Unitaid, Monell Chemical Senses Center, Emtricitabine, Gilead Sciences, CHAI, Partnership, Sofosbuvir, Prevalence, HIV, European and Developing Countries Clinical Trials Partnership, Bill & Melinda Gates Foundation, TAF, SOF, DBM, Global health, Research, Medicine, Doctor of Philosophy, Bangladesh Technical Education Board, UNIVERSAL, EDCTP, Foundation for the National Institutes of Health, MD, Patient, Child, Viral, Developing country, Science, Mortality, Pediatrics, Technology transfer, Caregiver, Pharmaceutical industry, Vaccine

For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research.

Key Points: 
  • For more than 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research.
  • However, just over 50% of them are on antiretroviral treatment compared to 76% of adults living with HIV on treatment today.
  • Many LMICs have a high burden of mother-to-child transmission and the prevalence of HIV among children remains high.
  • “By developing medicine formulations that meet the needs of children, and by improving palatability, through these partnership, we have the ability to potentially increase adherence rates in children.

Ascletis Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication

Retrieved on: 
Wednesday, October 26, 2022
National Institute, Monkeypox virus, Molnupiravir, Ribavirin, Illinois Institute of Technology, Lazzaro Spallanzani National Institute for Infectious Diseases, Omicron, Disease, Risk, Phases of clinical research, Caco-2, IND, Infection, HKEX, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Research, Investigational New Drug, NHC, Permeability, Monkeypox, WHO, Food, World, Orthopoxvirus, Sofosbuvir, Degenerative disease, Mefloquine, Region (Europe), CEO, Patent, IIT Research Institute, BioRxiv, World Health Organization, FDA, COVID-19, Atovaquone, Pharmaceutical industry, Vaccine, Technology

HANGZHOU and SHAOXING, China, Oct. 26, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the Investigational New Drug (IND) application of ASC10, an oral antiviral drug candidate targeting viral polymerase of monkeypox virus, has been filed with the U.S. Food and Drug Administration (FDA).

Key Points: 
  • ASC10 is an orally bioavailable and broad antiviral spectrum double prodrug which has a new and differentiated chemical structure from the single prodrug molnupiravir.
  • Ascletis has filed multiple patent applications globally for ASC10 and its use in viral diseases including monkeypox virus infection.
  • The data from the in vitro antiviral cellular assay with infectious monkeypox virus demonstrated that ASC10-A has potent antiviral activity against monkeypox virus, suggesting that ASC10 has the potential to be an effective treatment of monkeypox virus infection.
  • This IND filing of ASC10 for monkeypox in the U.S. will further broaden Ascletis' pipeline portfolio in viral diseases, and may provide a solution to monkeypox virus infections."

NuCana Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, August 17, 2022
Protide, U.S. Securities and Exchange Commission, Forward-looking statement, GLOBE, Private Securities Litigation Reform Act, SEC, Cancer, PD-1, Patent, Sofosbuvir, Politics of Poland, Security (finance), Neoplasm, Compliance, Patient, Irinotecan, Company, Therapy, Bevacizumab, NASDAQ, Organic acid, Goal, Commencement (album), NCNA, Colorectal cancer, Terminology, Renewable energy, Pharmaceutical industry, Food delivery

EDINBURGH, United Kingdom, Aug. 17, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

Key Points: 
  • EDINBURGH, United Kingdom, Aug. 17, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics.
  • As of June 30, 2022, NuCana had cash and cash equivalents of 46.5 million compared to 52.6 million as of March 31, 2022 and 60.3 million at December 31, 2021.
  • NuCana continues to advance its various clinical programs and reported a net loss of 3.9 million for the quarter ended June 30, 2022, as compared to a net loss of 9.1 million for the quarter ended June 30, 2021.
  • Basic and diluted loss per share was 0.07 for the quarter ended June 30, 2022, as compared to 0.17 per share for the quarter ended June 30, 2021.

German Court Rules that Gilead’s Sofosbuvir Infringes NuCana’s ‘190 Patent

Retrieved on: 
Monday, July 11, 2022
Politics of Poland, Private Securities Litigation Reform Act, Terminology, Sofosbuvir, U.S. Securities and Exchange Commission, Judgement, Protide, Company, Goal, Forward-looking statement, Counterclaim, Gilead Sciences, Cancer, NCNA, Sale, GLOBE, Patient, European Patent Convention, SEC, Court, EPO, UC, Security (finance), NASDAQ, Pharmaceutical industry

This judgement follows Gileads unsuccessful challenge to the validity of NuCanas 190 patent at the Opposition Division of the European Patent Office in 2021.

Key Points: 
  • This judgement follows Gileads unsuccessful challenge to the validity of NuCanas 190 patent at the Opposition Division of the European Patent Office in 2021.
  • By reference to the appeal pending before the EPO, Gilead also attempted to challenge the validity of the 190 patent in the German litigation.
  • However, the Court rejected each and every one of Gileads claims and fully endorsed the decision by the Opposition Division.
  • NuCanas patent filing, which was invented by Professor Chris McGuigan, precedes Gileads first filing date on its Sovaldi patents by several years.

Neuron23 Appoints Kathy Dong, Pharm.D., MBA to Board of Directors

Retrieved on: 
Tuesday, June 14, 2022
Ledipasvir/sofosbuvir, CA, Sanofi, Company, MBA, Pharming, Inflammation, Hepatitis B, CEO, Neurodegeneration, Rutgers University, Parkinson's disease, Therapy, Sofosbuvir, Multimedia, University, True North Sports & Entertainment, Patient, Genetics, Acquisition, Gilead Sciences, SAN, Drug discovery, True north, Pharmaceutical industry, Management

SOUTH SAN FRANCISCO, Calif., June 14, 2022 /PRNewswire/ -- Neuron23™ Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the appointment of Kathy Dong, Pharm.D., MBA, to its board of directors. Dr. Dong, who currently serves as the chief operating officer of Star Therapeutics, has a long track record of leading successful preclinical and clinical development programs and multiple product launches.    

Key Points: 
  • "I am thrilled to welcome someone of Kathy's caliber and expertise to Neuron23's board of directors," said Nancy Stagliano, Ph.D., CEO of Neuron23.
  • "For the past 15 years, Kathy has progressed programs into the clinic and to market, many of which have led to significant scientific and medical advances.
  • "I'm honored to join the Neuron23 board of directors at this pivotal time," said Dr. Dong.
  • Neuron23 Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases.

Informa Pharma Intelligence Launches 30th Edition Pharma R&D Annual Review

Retrieved on: 
Thursday, March 24, 2022
HCV, Degenerative disease, Plasma protein binding, D, Growth, Clinical trial, AAV, Nass, Drug pipeline, Novartis, Cancer, Lloyd, Intelligence, Rare, Roche, Pulse, Finger, Industry, Travel, Infection, Cell, COVID-19, Sofosbuvir, Sporting News Player of the Year Award, GLOBE, CD274, Company, NAS, PD-L1, Disease, Lilly, Gene, Fine chemical, Pharmaceutical industry, Medical device

NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) -- Informa Pharma Intelligence , the global business intelligence provider for the biopharma industry, today announced the launch of its 30 th Edition Pharma R&D Annual Review .

Key Points: 
  • NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) -- Informa Pharma Intelligence , the global business intelligence provider for the biopharma industry, today announced the launch of its 30 th Edition Pharma R&D Annual Review .
  • Novartis has 64.8% of its pipeline targeting rare diseases, the highest of any top 10 pharma, with Lilly the lowest, at 28.2%.
  • [2004 Pharma R&D Report]
    Sovaldi (sofosbuvir), Gileads first-in-class small molecule for hepatitis-C, was in our list of novel NASs from 2013.
  • [2021 Pharma R&D Report]
    For more information, or to view the current and past reports, visit Informa Pharma Intelligence or contact [email protected] .

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Retrieved on: 
Monday, February 28, 2022
PLOS Neglected Tropical Diseases, HIV disease progression rates, Fever Dream, Conference call, RNA, Niran, COVID-19, Company, Sofosbuvir, Dengue fever, Severe acute respiratory syndrome coronavirus 2, Atea, RZR, Viremia, Nasdaq, Nature Communications, Survival, Research, Development, NS5A, Dengue virus, Viral load, Income tax, Safety, SOF, Founder, Patient, Yellow, Clinical trial, RNA polymerase II, Program, Cash, Doctor of Philosophy, HCV, PLOS, Administration, Lists of academic journals, Vital signs, Preclinical development, Alpha, BID, Protease, State Administrative Expenses, GLOBE, Income, IV, Adult, Antimicrobial Agents and Chemotherapy, Conference, PK, Infection, Time, Pharmaceutical industry, Medical device, Vaccine, Pharmacokinetics, Merck, Pharmacodynamics

BOSTON, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.   

Key Points: 
  • ET today
    BOSTON, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.
  • Importantly, we have the financial strength and a seasoned management team to advance these programs through key clinical and regulatory inflection points, concluded Dr. Sommadossi.
  • Bemnifosbuvir Development Summary: In 2021, Atea reported data from two monotherapy Phase 2 clinical trials evaluating bemnifosbuvir for the treatment of COVID-19.
  • In addition, the Company recorded a $25.0 million expense during the fourth quarter 2021 due to an upfront payment related to the in-license of ruzasvir from Merck.